Scarica l'app Stockscreener
148.42
0.64%
-0.91
Precedente Chiudi:
$149.33
Aprire:
$148.36
Volume 24 ore:
115.27K
Relative Volume:
0.62
Capitalizzazione di mercato:
$5.97B
Reddito:
-
Utile/perdita netta:
$-77.61M
Rapporto P/E:
-64.59
EPS:
-2.2979
Flusso di cassa netto:
-
1 W Prestazione:
-3.66%
1M Prestazione:
+7.40%
6M Prestazione:
-5.46%
1 anno Prestazione:
+134.70%
Intervallo 1D:
$145.23
$154.16
Intervallo di 1 settimana:
$145.23
$158.90
Portata 52W:
$59.12
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BLTE vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
148.83 | 5.99B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
480.89 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
661.33 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
181.75 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.70 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Iniziato | BofA Securities | Buy |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-02 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Neutral |
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Mostra tutto
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease - Yahoo Finance
Belite Bio at Piper Sandler ophthalmology day: drug data support filing - Investing.com India
Belite Bio Slumps As Market Turmoil Trumps Drug Hopes - TipRanks
How Phase 3 DRAGON Trial Data Showcases At Major Conferences At Belite Bio (BLTE) Has Changed Its Investment Story - Sahm
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - markets.businessinsider.com
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - The Manila Times
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire Inc.
Responsive Playbooks and the BLTE Inflection - Stock Traders Daily
Price to earnings forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
BLTE Stock Price, Quote & Chart - ChartMill
Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE) - TradingView
Understanding the Setup: (BLTE) and Scalable Risk - Stock Traders Daily
Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued - Sahm
H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
Top Executive Makes Major Move With Belite Bio Stock Sale - TipRanks
Belite Bio CMO Scholl sells over $1.45m in company shares - Investing.com Nigeria
Form 4 Belite Bio Inc ADR For: 22 June By Investing.com - Investing.com South Africa
Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market - Stock Titan
Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant - Sahm
BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE) - Stock Titan
Belite Bio Soars After Key FDA Filing Milestone - TipRanks
Belite Bio CMO Scholl sells $1.4m shares from $137.61 to $145.02 - Investing.com India
Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946 - Stock Titan
BLTE (NASDAQ: BLTE) files Rule 144 notice to sell 10,000 ADS under vested RSUs - Stock Titan
Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG) - The Globe and Mail
BLTE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $200 - GuruFocus
The Technical Signals Behind (BLTE) That Institutions Follow - Stock Traders Daily
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (NASDAQ: BLTE) completes FDA NDA submission for tinlarebant in Stargardt disease - Stock Titan
Belite Bio (BLTE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Belite Bio Shares Surge on Drug Filing Hopes - TipRanks
Precision Trading with Belite Bio Inc (BLTE) Risk Zones - Stock Traders Daily
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
Why Belite Bio Stock Is Sinking Again Today - TipRanks
Belite Bio Stock Tumbles as Wall Street Cools - TipRanks
Belite Bio Stock Slumps On Mounting Doubts - TipRanks
Belite Bio (BLTE) Hovers Near Resistance as Price Action Remains MutedBear Flag - The Legal Advocate
H.C. Wainwright Sticks to Their Buy Rating for Opko Health (OPK) - The Globe and Mail
BLTE - Finviz
Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK
Mizuho lowers Belite Bio stock price target to $215 on valuation By Investing.com - Investing.com South Africa
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo
Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.43%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):